新型口服抗凝剂治疗椎动脉夹层：病例报告
Novel Oral Anticoagulants as Treatment for Vertebral Artery Dissection: Case Report.
作者信息
Góngora-Rivera Fernando, Martínez Héctor R, Cantu-Martinez Leonel, Camara-Lemarroy Carlos R, Moreno-Andrade Talía
机构信息
Servicio de Neurología del Hospital Universitario Dr. José Eleuterio González de la Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.
Instituto de Neurologia y Neurocirugia, Facultad de Medicina y Ciencias de la Salud, Instituto Tecnologico de Monterrey, Nuevo León, México.
出版信息
J Vasc Interv Neurol. 2018 Nov;10(2):56-58.
BACKGROUND AND PURPOSE
Cervical artery dissections, which may be traumatic or spontaneous, account for a significant proportion of strokes in the young. Antithrombotic therapy is the mainstay of treatment, but new oral anticoagulants could be an alternative treatment to the optimal strategy of anticoagulation followed by antiplatelet drugs.
SUMMARY OF CASE
We report the case of a 40-year-old patient with a spontaneous vertebral artery dissection who developed a cerebellar ischemic stroke, who had a favorable outcome and complete vessel recanalization after three months of treatment with the oral factor Xa inhibitor rivaroxaban.
CONCLUSION
New oral anticoagulant could constitute an alternative and new therapeutic option in cervical artery dissections.
背景与目的
颈动脉瘤夹层形成，可能是外伤性或自发性的，在年轻人中风中占相当大的比例。抗血栓治疗是主要的治疗方法，但新型口服抗凝剂可能是抗凝治疗后使用抗血小板药物这一最佳策略的替代治疗方法。
病例摘要
我们报告一例40岁自发性椎动脉夹层形成患者，该患者发生了小脑缺血性中风，经口服Xa因子抑制剂利伐沙班治疗三个月后，取得了良好的疗效，血管完全再通。
结论
新型口服抗凝剂可能成为颈动脉瘤夹层形成的一种替代且新的治疗选择。
Zotero 插件